EpiCast Report：小細胞肺がん (SCLC) - 2024年までの疫学予測
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
|出版日||ページ情報||英文 47 Pages
|EpiCast Report：小細胞肺がん (SCLC) - 2024年までの疫学予測 EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024|
|出版日: 2016年01月01日||ページ情報: 英文 47 Pages||
世界の主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本）で小細胞肺がん (SCLC) と診断された発症件数は、2014年の79,077件から、2024年には91,640件まで、年間成長率で1.59％の増加が予測されています。
当レポートでは、世界の主要7ヶ国における小細胞肺がん (SCLC) について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。
Small Cell Lung Cancer (SCLC) is a distinct form of lung cancer that typically initially presents in the central airways before spreading to the submucosa, which leads to the narrowing of airways. SCLC is considered to be highly malignant due to its cell composition that causes faster doubling time, earlier development of metastases, and worsened prognosis when compared with other lung cancer types. SCLC is widely considered to account for 15% of all lung cancer cases, with the other lung cancer cases being predominantly caused by non-small cell lung cancer (NSCLC). SCLC is typically presented in two main stages, limited stage (LS-SCLC) and extensive stage (ES-SCLC).
GlobalData epidemiologists forecast that the diagnosed incident cases of SCLC will increase from 79,077 cases in 2014 to 91,640 cases in 2024 across the 7MM with an Annual Growth Rate (AGR) of 1.59%. The US had the highest proportion of SCLC diagnosed incident cases out of the 7MM throughout the forecast period. In 2014, there were 23,361 LS-SCLC diagnosed incident cases and 55,716 ES-SCLC diagnosed incident cases in the 7MM, accounting for 29.54% and 70.46% of the total SCLC diagnosed incident cases, respectively. Further, GlobalData epidemiologists forecast that the five-year diagnosed prevalent cases of SCLC will increase from 59,330 cases in 2014 to 71,528 cases in 2024 with an AGR of 2.06%. Out of the 7MM, Japan had the highest proportion of SCLC five-year diagnosed prevalent cases across the forecast period.
GlobalData's epidemiological forecast for the diagnosed incident and the five-year diagnosed prevalent cases of SCLC in the 7MM is supported by age- and sex-specific incidence data obtained for the individual markets. Further, the analysis was strengthened by the use of a consistent methodology and definition of lung cancer for the diagnosed incident cases in the SCLC forecast, and using linear regression techniques when suitable. In addition, the forecast is based on age-, sex-, and market-specific historical data points obtained from the NCC, CI5plus, ITACAN, SEER, and ZfKD databases. The use of a consistent methodology across the 7MM to forecast the total diagnosed incident cases, and the five-year diagnosed prevalent cases of SCLC, allows for a meaningful comparison of the forecast incident cases and the forecast five-year prevalent cases of SCLC across the 7MM. Further, GlobalData epidemiologists provided the diagnosed incident cases of SCLC in the 7MM segmented into LS-SCLC and ES-SCLC at diagnosis.
The Small Cell Lung Cancer (SCLC) EpiCast report will allow you to -